Cargando…
The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis
BACKGROUND: Immunoglobulin light chain (AL) amyloidosis is a rare, multi-systemic disorder characterized by two disease processes: an underlying plasma cell dyscrasia that provides the source of pathologic light chains, and the resulting organ dysfunction caused by deposition of amyloid light chain...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523334/ https://www.ncbi.nlm.nih.gov/pubmed/32993758 http://dx.doi.org/10.1186/s13023-020-01525-2 |